Drug profile · INN
etodolac
LODINE
etodolac (LODINE) is a cyclooxygenase-2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — etodolac
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 1
- Data quality
- 0.89
Quick answer
etodolac (LODINE) is a cyclooxygenase-2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase-2 inhibitor
Primary target: Prostaglandin G/H synthase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is etodolac?
etodolac (LODINE) is a cyclooxygenase-2 inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for etodolac?
LODINE is a marketed brand name for etodolac. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etodolac?
etodolac has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.